JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB108730

Human Anti-Epstein Barr virus IgG ELISA Kit (EBV-VCA)

5

(1 Review)

|

(7 Publications)

Human Anti-Epstein Barr virus IgG ELISA Kit (EBV-VCA) is an indirect ELISA for the qualitative detection of IgG class antibodies against Epstein Barr virus (EBV-VCA) in human plasma and serum samples.

- Colorimetric readout - 450 nm - Works on any standard plate reader
- Easy results interpretation
- Cut-off, positive and negative controls included

Key facts

Detection method

Colorimetric

Sample types

Citrate plasma, Heparin Plasma, Serum

Reacts with

Human

Assay type

Indirect

Assay Platform

Microplate

style
left-column

Complementary Products

Assay Kits

AB108731

Human Anti-Epstein Barr virus IgG ELISA Kit (EBV-EBNA)

  • 0
  • 0
Assay Kits

AB108732

Human Anti-Epstein Barr virus IgM ELISA Kit (EBV-VCA)

  • 0
  • 0
Assay Kits

AB108724

Human Anti-Cytomegalovirus IgG ELISA Kit (CMV)

  • 5
  • 2
Assay Kits

AB108782

Human Anti-Varicella-Zoster virus IgG ELISA Kit (VZV)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Human Anti-Epstein Barr virus IgG ELISA Kit (EBV-VCA) ab108730 is an indirect ELISA for the qualitative detection of Human Anti-Epstein Barr virus IgG (EBV-VCA) antibodies in serum, plasma.

How the assay works:

A 96-well plate has been precoated with Epstein Barr virus antigens to bind cognate antibodies. Controls or test samples are added to the wells and incubated. Following washing, a horseradish peroxidase (HRP) labelled anti-Human IgG conjugate is added to the wells, which binds to the immobilized Epstein Barr virus-specific antibodies. TMB is then catalyzed by the HRP to produce a blue color product that changes to yellow after adding an acidic stop solution. The density of yellow coloration is directly proportional to the amount of Epstein Barr virus IgG sample captured in plate.

Assay Specificity

Our ELISA kits are rigorously validated to ensure the highest level of consistency and reproducibility. Please check the protocol booklet for more details

Human Anti-Epstein Barr virus IgG ELISA Kit (EBV-VCA) ab108730 protocol summary

1. Add samples and controls to wells used. Incubate at 37°C
2. Wash each well and add prepared labeled HRP-Conjugate. Incubate at room temperature
3. After washing, add TMB substrate solution to each well. Incubate at room temperature
4. Add Stop Solution to each well. Read immediately.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

style
left-column

Precision

[ { "reproducibilityType": "Inter", "sample": "Serum", "replicates": 15, "mean": null, "standardDeviation": null, "coefficientOfVariability": "4.3" }, { "reproducibilityType": "Intra", "sample": "Serum", "replicates": 10, "mean": null, "standardDeviation": null, "coefficientOfVariability": "2.9" } ]
style
left-column

What's included?

{ "values": { "1x96Tests": { "sellingSize": "1 x 96 Tests", "publicAssetCode":"ab108730-1x96Tests", "assetComponentDetails": [ { "size":"1 x 20 mL", "name":"Epstein Barr virus anti-IgG HRP Conjugate", "number":"AB108730-CMP04", "productcode":"" }, { "size":"1 x 2 mL", "name":"Epstein-Barr Virus IgG Negative Control", "number":"AB108730-CMP08", "productcode":"" }, { "size":"1 x 100 mL", "name":"IgG Sample Diluent", "number":"AB108730-CMP01", "productcode":"" }, { "size":"1 x 3 mL", "name":"Epstein-Barr Virus IgG Cut-off Control", "number":"AB108730-CMP07", "productcode":"" }, { "size":"1 x 2 mL", "name":"Epstein-Barr Virus IgG Positive Control", "number":"AB108730-CMP06", "productcode":"" }, { "size":"1 x 50 mL", "name":"20X Washing Solution", "number":"AB108730-CMP10", "productcode":"" }, { "size":"1 x 15 mL", "name":"Stop Solution", "number":"AB108730-CMP11", "productcode":"" }, { "size":"1 x 15 mL", "name":"TMB Substrate Solution", "number":"AB108730-CMP09", "productcode":"" }, { "size":"1 x 1 Unit", "name":"Strip holder", "number":"AB108730-CMP02", "productcode":"" }, { "size":"1 x 1 Unit", "name":"Cover foil", "number":"AB108730-CMP03", "productcode":"" }, { "size":"1 x 1 Unit", "name":"Epstein Barr virus (IgG) Coated Microplate (12 x 8 wells)", "number":"AB108730-CMP05", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
+4°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Epstein-Barr Virus (EBV) VCA IgG antibodies are molecular indicators developed by the immune system in response to the structural proteins of the viral capsid of EBV particularly the viral capsid antigen (VCA). These proteins facilitate the formation of the viral shell. VCA IgG antibodies typically have a mass of approximately 150 kDa and are expressed during the acute and convalescent phases of EBV infection. The presence of these antibodies can often be found in serum samples indicating past infection since VCA IgG appears late and persists for a lifetime.
Biological function summary

EBV VCA IgG antibodies participate in the immune surveillance mechanism against the EBV. They belong to the immunoglobulin class and indicate an adaptive immune response helping to neutralize viral particles and prevent EBV from causing further infection. These antibodies do not work as part of a larger complex but operate independently to tag viral particles for destruction by immune cells. The detection of these antibodies therefore serves as a marker for prior EBV exposure and helps assess the immune status of individuals.

Pathways

EBV VCA IgG antibodies primarily influence immune response pathways particularly the humoral immune response. They do not directly participate in signaling pathways but result from the activity of B cells within the adaptive immune system as they recognize EBV VCA. B cell differentiation and activation are closely related and proteins like CD20 and CD19 are important in this process as they support the proliferation and development of antibody-producing cells.

EBV VCA IgG antibodies relate directly to infectious mononucleosis a condition commonly caused by EBV. A high level of these antibodies indicates a past or ongoing EBV infection and can aid in the diagnosis of mononucleosis. Furthermore chronic active EBV infection can be represented by persistent high titer levels of EBV VCA IgG. It is essential to acknowledge the connection of these antibodies to EBV-associated cancers such as Burkitt's lymphoma where EBV contributes to the oncogenic process along with other proteins like LMP1 (latent membrane protein 1) which play significant roles in tumorigenesis.
style
left-column

Product protocols

style
left-column

Target data

style
left-column

Publications (7)

Recent publications for all applications. Explore the full list and refine your search

Open forum infectious diseases 11:ofae693 PubMed39703789

2024

Herpesvirus Antibodies Are Correlated With Greater Expression of p16 in the T Cells of Humans.

Applications

Unspecified application

Species

Unspecified reactive species

Grace Noppert,Kathleen Wragg,Chihua Li,Kate Duchowny,Lona Mody,Allison E Aiello,Linda Nyquist,Martin O'Brien,Raymond Yung,Daniel Goldstein

Journal of inflammation (London, England) 21:30 PubMed39135051

2024

Evidence of aberrant anti-epstein-barr virus antibody response, though no viral reactivation, in people with post-stroke fatigue.

Applications

Unspecified application

Species

Unspecified reactive species

Isobel C Mouat,Li Zhu,Alperen Aslan,Barry W McColl,Stuart M Allan,Craig J Smith,Marion S Buckwalter,Laura McCulloch

Journal of immunology research 2022:4363927 PubMed36405008

2022

Low Level of Advanced Glycation End Products in Serum of Patients with Allergic Rhinitis and Chronic Epstein-Barr Virus Infection at Different Stages of Virus Persistence.

Applications

Unspecified application

Species

Unspecified reactive species

Svitlana Zubchenko,Iryna Kril,Halyna Potemkina,Anna Havrylyuk,Aleksandra Kuzan,Andrzej Gamian,Valentyna V Chopyak

Immunity 54:99-115.e12 PubMed33271118

2020

Comprehensive Profiling of an Aging Immune System Reveals Clonal GZMK CD8 T Cells as Conserved Hallmark of Inflammaging.

Applications

Unspecified application

Species

Unspecified reactive species

Denis A Mogilenko,Oleg Shpynov,Prabhakar Sairam Andhey,Laura Arthur,Amanda Swain,Ekaterina Esaulova,Simone Brioschi,Irina Shchukina,Martina Kerndl,Monika Bambouskova,Zhangting Yao,Anwesha Laha,Konstantin Zaitsev,Samantha Burdess,Susan Gillfilan,Sheila A Stewart,Marco Colonna,Maxim N Artyomov

BMC public health 20:912 PubMed32532296

2020

Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom.

Applications

Unspecified application

Species

Unspecified reactive species

Ashvin Kuri,Benjamin Meir Jacobs,Nikki Vickaryous,Julia Pakpoor,Jaap Middeldorp,Gavin Giovannoni,Ruth Dobson

Neurology(R) neuroimmunology & neuroinflammation 5:e458 PubMed29629396

2018

Anti-NMDA receptor encephalitis and nonencephalitic HSV-1 infection.

Applications

Unspecified application

Species

Unspecified reactive species

Amy Salovin,Jason Glanzman,Kylie Roslin,Thais Armangue,David R Lynch,Jessica A Panzer

Nature communications 8:1473 PubMed29133794

2017

Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA.

Applications

Unspecified application

Species

Unspecified reactive species

Yuan Tian,Mariana Babor,Jerome Lane,Veronique Schulten,Veena S Patil,Grégory Seumois,Sandy L Rosales,Zheng Fu,Gaelle Picarda,Julie Burel,Jose Zapardiel-Gonzalo,Rashika N Tennekoon,Aruna D De Silva,Sunil Premawansa,Gayani Premawansa,Ananda Wijewickrama,Jason A Greenbaum,Pandurangan Vijayanand,Daniela Weiskopf,Alessandro Sette,Bjoern Peters
View all publications
style
left-column
style
left-column
websiteProtocolBooklet
en
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com